FR2271821B1 - - Google Patents

Info

Publication number
FR2271821B1
FR2271821B1 FR7503076A FR7503076A FR2271821B1 FR 2271821 B1 FR2271821 B1 FR 2271821B1 FR 7503076 A FR7503076 A FR 7503076A FR 7503076 A FR7503076 A FR 7503076A FR 2271821 B1 FR2271821 B1 FR 2271821B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7503076A
Other languages
French (fr)
Other versions
FR2271821A1 (US07160377-20070109-C00002.png
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP1295374A external-priority patent/JPS539228B2/ja
Priority claimed from JP1295474A external-priority patent/JPS539229B2/ja
Priority claimed from JP1511574A external-priority patent/JPS539230B2/ja
Priority claimed from JP1511674A external-priority patent/JPS538705B2/ja
Priority claimed from JP1595374A external-priority patent/JPS539231B2/ja
Priority claimed from JP1978774A external-priority patent/JPS5310987B2/ja
Priority claimed from JP2360474A external-priority patent/JPS539232B2/ja
Priority claimed from JP3071774A external-priority patent/JPS5625570B2/ja
Priority claimed from JP3071874A external-priority patent/JPS5146650B2/ja
Priority claimed from JP5831574A external-priority patent/JPS5310990B2/ja
Priority claimed from JP5831774A external-priority patent/JPS5310991B2/ja
Priority claimed from JP6782474A external-priority patent/JPS5310995B2/ja
Priority claimed from JP6782374A external-priority patent/JPS5310994B2/ja
Priority claimed from JP13072174A external-priority patent/JPS5156467A/ja
Priority claimed from JP13072874A external-priority patent/JPS5156474A/ja
Priority claimed from JP13072374A external-priority patent/JPS5156469A/ja
Priority claimed from JP49130719A external-priority patent/JPS5156465A/ja
Priority claimed from JP13071774A external-priority patent/JPS5156463A/ja
Priority claimed from JP13072774A external-priority patent/JPS5156473A/ja
Priority claimed from JP13071874A external-priority patent/JPS5156464A/ja
Priority claimed from JP13072574A external-priority patent/JPS5156471A/ja
Priority claimed from JP13072274A external-priority patent/JPS5156468A/ja
Priority claimed from JP13072474A external-priority patent/JPS5156470A/ja
Priority claimed from JP14033974A external-priority patent/JPS5165770A/ja
Priority claimed from JP14034074A external-priority patent/JPS51125290A/ja
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of FR2271821A1 publication Critical patent/FR2271821A1/fr
Publication of FR2271821B1 publication Critical patent/FR2271821B1/fr
Application granted granted Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/32—Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7503076A 1974-01-31 1975-01-31 Expired FR2271821B1 (US07160377-20070109-C00002.png)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
JP1295374A JPS539228B2 (US07160377-20070109-C00002.png) 1974-01-31 1974-01-31
JP1295474A JPS539229B2 (US07160377-20070109-C00002.png) 1974-01-31 1974-01-31
JP1511574A JPS539230B2 (US07160377-20070109-C00002.png) 1974-02-05 1974-02-05
JP1511674A JPS538705B2 (US07160377-20070109-C00002.png) 1974-02-05 1974-02-05
JP1595374A JPS539231B2 (US07160377-20070109-C00002.png) 1974-02-07 1974-02-07
JP1978774A JPS5310987B2 (US07160377-20070109-C00002.png) 1974-02-18 1974-02-18
JP2360474A JPS539232B2 (US07160377-20070109-C00002.png) 1974-02-27 1974-02-27
JP3071874A JPS5146650B2 (US07160377-20070109-C00002.png) 1974-03-18 1974-03-18
JP3071774A JPS5625570B2 (US07160377-20070109-C00002.png) 1974-03-18 1974-03-18
JP5831774A JPS5310991B2 (US07160377-20070109-C00002.png) 1974-05-22 1974-05-22
JP5831574A JPS5310990B2 (US07160377-20070109-C00002.png) 1974-05-22 1974-05-22
JP6782374A JPS5310994B2 (US07160377-20070109-C00002.png) 1974-06-13 1974-06-13
JP6782474A JPS5310995B2 (US07160377-20070109-C00002.png) 1974-06-13 1974-06-13
JP13071774A JPS5156463A (ja) 1974-11-11 1974-11-11 Karubosuchirirujudotaino seizoho
JP13072774A JPS5156473A (ja) 1974-11-11 1974-11-11 Karubosuchirirujudotaino seizoho
JP13071874A JPS5156464A (ja) 1974-11-11 1974-11-11 Karubosuchirirujudotaino seizoho
JP13072174A JPS5156467A (en) 1974-11-11 1974-11-11 55 * arufua haroarukanoiru * 88 arukokishi 3 44 jihidorokarubosuchiriruno seizoho
JP13072274A JPS5156468A (en) 1974-11-11 1974-11-11 55 * arufua arukiruaminoarukanoiru * 88 arukokishi 3*44 jihidorokarubosuchirirunoseizoho
JP13072874A JPS5156474A (ja) 1974-11-11 1974-11-11 Karubosuchirirujudotaino seizoho
JP13072474A JPS5156470A (en) 1974-11-11 1974-11-11 55 * 22 arukiruamino 11 hidorokishi * arukiru 88 hidorokishi 3 44 jihidorokarubosuchiriruno seizoho
JP13072574A JPS5156471A (en) 1974-11-11 1974-11-11 55 * 22 ararukiruamino 11 hidorokishi * arukiru 88 hidorokishi 3 44 jihidorokarubosuchiriruno seizoho
JP49130719A JPS5156465A (en) 1974-11-11 1974-11-11 Karubosuchirirujudotaino seizoho
JP13072374A JPS5156469A (en) 1974-11-11 1974-11-11 55 * arufua arukiruaminoarukanoiru * 88 hidorokishi 3 44 jihidorokarubosuchirirunoseizoho
JP14033974A JPS5165770A (ja) 1974-12-04 1974-12-04 Karubosuchirirujudotaino seizoho
JP14034074A JPS51125290A (en) 1974-12-04 1974-12-04 A process for preparing carbostyryl

Publications (2)

Publication Number Publication Date
FR2271821A1 FR2271821A1 (US07160377-20070109-C00002.png) 1975-12-19
FR2271821B1 true FR2271821B1 (US07160377-20070109-C00002.png) 1978-08-04

Family

ID=27586766

Family Applications (3)

Application Number Title Priority Date Filing Date
FR7502169A Expired FR2259610B1 (US07160377-20070109-C00002.png) 1974-01-31 1975-01-23
FR7503076A Expired FR2271821B1 (US07160377-20070109-C00002.png) 1974-01-31 1975-01-31
FR7510005A Granted FR2274303A1 (fr) 1974-01-31 1975-03-28 Nouveaux (hydroxy-1 (amino substitue)-2 alkyl)-5 hydroxy-8 dihydro-3, 4 carbostyriles, leur procede de preparation et leur utilisation therapeutique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR7502169A Expired FR2259610B1 (US07160377-20070109-C00002.png) 1974-01-31 1975-01-23

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR7510005A Granted FR2274303A1 (fr) 1974-01-31 1975-03-28 Nouveaux (hydroxy-1 (amino substitue)-2 alkyl)-5 hydroxy-8 dihydro-3, 4 carbostyriles, leur procede de preparation et leur utilisation therapeutique

Country Status (4)

Country Link
US (2) US4026897A (US07160377-20070109-C00002.png)
DE (2) DE2461596A1 (US07160377-20070109-C00002.png)
FR (3) FR2259610B1 (US07160377-20070109-C00002.png)
GB (4) GB1496872A (US07160377-20070109-C00002.png)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
CH619453A5 (US07160377-20070109-C00002.png) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
JPS609713B2 (ja) * 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
JPS5513241A (en) * 1978-07-14 1980-01-30 Otsuka Pharmaceut Co Ltd Remedy for glaucoma
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
US4322425A (en) * 1980-03-14 1982-03-30 Otsuka Pharmaceutical Co., Ltd. Compositions for treating glaucoma
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
FI77852C (fi) * 1981-02-17 1989-05-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat.
IT1121651B (it) * 1981-10-13 1986-04-10 Chiesi Farma Spa Procedimento per la preparazione del 5-(1-idrossi-2-imopropilammino)butil-8-idrossi-carbostirile(procaterolo)
US4578381A (en) * 1982-07-05 1986-03-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
AU565621B2 (en) * 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
US4616022A (en) * 1984-08-17 1986-10-07 Warner-Lambert Company Procaterol stabilization
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
DK167187A (da) 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
US4687776A (en) * 1986-10-24 1987-08-18 Warner-Lambert Company Drug stabilization
ZA882783B (en) * 1987-06-10 1988-10-20 Warner-Lambert Company Process for preparing a pharmaceutical composition
WO1993013049A1 (fr) * 1991-12-20 1993-07-08 Karin Elisabeth Peuschel Emploi de l'effet immunoactivant de 3-naphthyloxy-2-hydroxy-propylamines, interessant specialement pour l'immunite cellulaire, par exemple contre infections virales
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
US7358244B2 (en) * 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US7307076B2 (en) * 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US20090029958A1 (en) * 2006-03-08 2009-01-29 Lilian Alcaraz Phenethanolamine derivatives as beta2 adrenoreceptor agonists
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
TW200902091A (en) * 2007-05-18 2009-01-16 Tti Ellebeau Inc Systems, devices, and methods for passive transdermal delivery of active agents to a biological interface
DE602008005462D1 (de) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
PL2178513T3 (pl) * 2007-06-22 2011-09-30 Bristol Myers Squibb Holdings Ireland Kompozycje w tabletkach zawierające atazanawir
KR101686243B1 (ko) * 2007-06-22 2016-12-13 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 아타자나비르를 함유하는 정제 조성물
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
DK2925725T3 (en) 2012-12-03 2017-01-16 Pfizer androgen receptor modulators
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP2016511744A (ja) * 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN106279018B (zh) * 2015-06-26 2019-01-29 沈阳药科大学 β2-受体兴奋剂及其制备方法和应用
CN111217746B (zh) * 2020-03-10 2021-09-24 佛山市隆信医药科技有限公司 一种盐酸丙卡特罗的制备方法
CN114028330B (zh) * 2021-03-22 2023-03-31 南京艾德加生物制药科技有限公司 一种盐酸丙卡特罗口服溶液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770619A (en) * 1952-06-11 1956-11-13 Schenley Ind Inc Substituted 8-quinolinols
US3555030A (en) * 1964-11-25 1971-01-12 Smith Kline French Lab Muscle relaxant and analgesic compositions
NL148312B (nl) * 1965-03-10 1976-01-15 Pfizer Werkwijze voor het bereiden van een geneesmiddel dat een of een aantal 1-chinolyl-2-alkylaminoethanolderivaten en/of de zuuradditiezouten daarvan bevat en de onder toepassing van deze werkwijze verkregen gevormde geneesmiddelen, alsmede werkwijze voor het bereiden van deze geneeskrachtige derivaten en de zuuradditiezouten daarvan.
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
FR2163358A1 (en) * 1971-12-15 1973-07-27 Synthelabo Phenylalkanolamine derivs - with effects on the smooth musculature

Also Published As

Publication number Publication date
US4022776A (en) 1977-05-10
FR2259610B1 (US07160377-20070109-C00002.png) 1978-07-21
DE2461861A1 (de) 1975-08-07
GB1496874A (en) 1978-01-05
GB1496769A (en) 1978-01-05
FR2274303A1 (fr) 1976-01-09
FR2271821A1 (US07160377-20070109-C00002.png) 1975-12-19
FR2274303B1 (US07160377-20070109-C00002.png) 1980-02-22
GB1496872A (en) 1978-01-05
DE2461596A1 (de) 1975-11-27
FR2259610A1 (US07160377-20070109-C00002.png) 1975-08-29
GB1496766A (en) 1978-01-05
US4026897A (en) 1977-05-31

Similar Documents

Publication Publication Date Title
FR2259610B1 (US07160377-20070109-C00002.png)
FR2266917A1 (US07160377-20070109-C00002.png)
FR2264086A2 (US07160377-20070109-C00002.png)
FR2273647B1 (US07160377-20070109-C00002.png)
FR2295287B1 (US07160377-20070109-C00002.png)
FR2285720B1 (US07160377-20070109-C00002.png)
FR2259819A1 (US07160377-20070109-C00002.png)
JPS50101019A (US07160377-20070109-C00002.png)
FR2290356B1 (US07160377-20070109-C00002.png)
FR2265559B1 (US07160377-20070109-C00002.png)
FR2265672B1 (US07160377-20070109-C00002.png)
HU167561B (US07160377-20070109-C00002.png)
CS173230B1 (US07160377-20070109-C00002.png)
JPS50101292U (US07160377-20070109-C00002.png)
AU481340A (US07160377-20070109-C00002.png)
BG22309A1 (US07160377-20070109-C00002.png)
BG21632A1 (US07160377-20070109-C00002.png)
AU482019A (US07160377-20070109-C00002.png)
AU482110A (US07160377-20070109-C00002.png)
BG21503A1 (US07160377-20070109-C00002.png)
AU482332A (US07160377-20070109-C00002.png)
CH591164A5 (US07160377-20070109-C00002.png)
CH1357474A4 (US07160377-20070109-C00002.png)
CH1107074A4 (US07160377-20070109-C00002.png)
BG26152A1 (US07160377-20070109-C00002.png)

Legal Events

Date Code Title Description
CL Concession to grant licences
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0350, 920529

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0350, 750131

CL Concession to grant licences